Who makes Ropivacaine 0,375% in SFICB block?

Ropivacaine 0,375% in SFICB block is developed by University of Liege.

What development phase is Ropivacaine 0,375% in SFICB block in?

Ropivacaine 0,375% in SFICB block is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

Ropivacaine 0,375% in SFICB block

University of Liege · FDA-approved active Small molecule Quality 2/100

Ropivacaine 0.375% in SFICB block, marketed by the University of Liege, is a local anesthetic used in regional anesthesia. The key composition patent expires in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of reported revenue and key trial results, which may limit its commercial appeal and competitive positioning.

At a glance

Generic name	Ropivacaine 0,375% in SFICB block
Sponsor	University of Liege
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ropivacaine 0,375% in SFICB block CI brief — competitive landscape report
Ropivacaine 0,375% in SFICB block updates RSS · CI watch RSS
University of Liege portfolio CI